

Nottinghamshire Area Prescribing Committee

Benzodiazepines and Z-Hypnotics Guidance on Prescribing and Deprescribing

For the Management of Insomnia and Anxiety Disorders in Adults

Contents	Page
Key messages	2
Scope	2
Non pharmacological management of insomnia	2
Non pharmacological management of anxiety disorders	3
Prescribing Guidance for Primary Care	3
Prescribing Guidance for Secondary Care	4
Management and Review of Long Term Prescriptions	5
Benzodiazepine and Z-hypnotics de-prescribing algorithm	6-7
Driving	8
References and Version Control	8
Appendix One – Practical Sleep Hygiene for Inpatients	9-10
Appendix Two – Comparison of Benzodiazepines and Z-hypnotics	11

Benzodiazepines and Z-Hypnotics Guidance on Prescribing and Deprescribing



Nottinghamshire Area Prescribing Committee

2.1	Last reviewed: October 2025	Review date: September 2027
-----	-----------------------------	-----------------------------

Key messages

- Benzodiazepines and z-hypnotics are classed as medicines associated with **dependence or withdrawal symptoms**¹.
- Benzodiazepines are effective and **indicated for the short-term treatment of anxiety** that is severe, disabling, or causing the patient unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic, or psychotic illness².
- Z-hypnotics are effective for the **short-term treatment of insomnia**; when the insomnia is severe, disabling or causing the patient extreme distress³.
- The long-term use of benzodiazepines and z-hypnotics for insomnia and anxiety are of limited benefit and have **well documented harms including tolerance, dependence, risk of falls and cognitive impairment**^{2,3}.
- Before prescribing a benzodiazepine or z-hypnotic, explain the risks and have an agreed plan with the individual including information about how to stop the medicine.
- Non-pharmacological treatments including sleep hygiene and psychological approaches should be continued alongside prescribing.
- Established long term use of benzodiazepines and z-hypnotics should be proactively reviewed. Use [Should I stop my benzodiazepine or z-drug?](#) patient decision aid to support review⁷.

Scope

- Inclusions: The use of benzodiazepines for anxiety and/or insomnia and the use of z-hypnotics for insomnia
- Exclusions: The use of benzodiazepines for rapid tranquillisation, alcohol detoxification, end of life care, movement disorders, spasticity management, IV sedation for procedures, epilepsy and children and young people (<18 years of age)

Nonpharmacological management of anxiety

Optimise treatment for co-morbidities:

- Consider other triggers or factors associated with the anxiety (e.g., physical illness, other stressors, substance misuse).
- Review and optimise treatment for underlying mental health conditions such as depression and panic disorder.

Psychological Therapies:

- Low intensity psychological interventions (individual and facilitated self-help therapies) are recommended first line for the management of anxiety. See [NHS information on self-help for anxiety](#) and [NHS information on self-help therapies](#).
- Consider a referral to [NHS Nottingham and Nottinghamshire Talking Therapies](#). They offer various psychological interventions for the treatment of anxiety. The interventions on offer include therapist led digital interventions as well as face to face therapy for more complex cases. They accept GP and self-referral for people across Nottingham City and County.
Website: www.notts-talk.co.uk
Telephone: 0333 188 1060
- The **step 4 psychology service** provides psychological therapies for people who have mental health or psychological difficulties which are chronic and complex enough to be unsuitable for intervention with a lower step of care. They accept healthcare professional referral (including GPs) for people across Nottingham City, County North, and County South.
Website: <https://www.nottinghamshirehealthcare.nhs.uk/step-4-psychology-service/>

Other medicines (propranolol):

- Although NICE doesn't recommend propranolol in anxiety, propranolol is licensed for anxiety with symptoms such as palpitations, sweating and tremor. Propranolol is toxic in overdose and there is a potential under recognised risk of harm. It is not recommended for patients who are at risk of self-harm or suicide, including those with co-existing migraine, depression, or anxiety. If propranolol is prescribed for this group of patients, the smallest quantity should be supplied and the risk-benefits reviewed regularly. Further information is available from the [2020 Health Services Safety Investigation Body report](#).

Nonpharmacological management of insomnia

Sleep hygiene:

- Good sleep hygiene should be considered in all people with insomnia and should be continued alongside any hypnotic prescription.
- More information on [insomnia](#) is available from the [Patient.info website](#), and for [tips on sleep hygiene](#) check the [Mind website](#).
- Sleep diaries can be helpful for identifying sleeping patterns and lifestyle factors that may exacerbate or maintain insomnia. The diary should be kept for at least two weeks. Sleep diary templates are available on the [The Sleep Charity](#) website.
- See Appendix one for sleep hygiene advice specific to inpatient units.

Optimising treatment for co-morbidities:

- Consider other triggers or factors associated with the insomnia (e.g., physical illness, other stressors, substance misuse).
- If there is an underlying physical health condition such as pain, respiratory or cardiac disease, sleep problems are likely to improve when the condition has been adequately treated.
- Optimise any other medicines the person is taking that may be causing insomnia.

Psychological Therapies:

- Recommended first line for the treatment of chronic sleep problems. The benefits of psychological interventions for chronic insomnia often last well beyond the termination of active treatment⁴.
- Patients with insomnia and co-existing mental health conditions should be considered for referral to [NHS Nottingham and Nottinghamshire Talking Therapies](#) with an initial aim to focus on sleep.

Other medicines:

- Always check whether the patient takes any other prescribed or over the counter medicines to aid sleep (these may interact with benzodiazepines and z-hypnotics to cause additive side effects, present an increased risk of overdose and potential for misuse when used concomitantly).
- Sedating antihistamines such as promethazine (Phenergan[®], Sominex[®]) are only licensed for temporary sleeping difficulties (1-2 weeks) and are not appropriate for the management of chronic insomnia.
- Sedating antidepressants are not licensed for the treatment of insomnia and are not recommended to be prescribed unless treating an appropriate co-morbidity.
- Daridorexant is licensed for adults with insomnia characterized by symptoms presenting for at least 3 months and considerable impact on daytime functioning. It is recommended by NICE if cognitive behavioral therapy for insomnia (CBTi) has been tried, but not worked, or if CBTi is not available or unsuitable. A [prescribing information sheet](#) is available.

Prescribing Principles – Primary Care

- Reserve benzodiazepine and z-hypnotic prescribing for short courses to alleviate severe, disabling symptoms.
- If a prescription is required it should be limited to a short period (no longer than two weeks, preferably less than one week).
- Use the lowest effective dose for the shortest possible period.
- Inform the patient that further prescriptions for z-hypnotics and benzodiazepines will not usually be given, ensure the reasons for this are understood and document this in the patient's notes.
- Do not issue further prescriptions without seeing the patient.
- Switching from one z-hypnotic to another should only occur if a patient experiences adverse effects considered to be directly related to the specific agent.
- Patients who have not responded to one z-hypnotic should not be prescribed any of the others.
- See Appendix 2 for a comparison of different benzodiazepines and z-hypnotics.
- Ensure discharge communication for benzodiazepine and z-hypnotic prescriptions is reviewed and action taken in a timely manner; new prescriptions not containing information on course duration/review should be queried with the discharging service.

Prescribing Principles – Secondary Care

On admission

- Determine whether the patient takes one or more of these medicines, regularly or intermittently for anxiety, insomnia, or both.
- Review the patient's use of benzodiazepines and z-hypnotics to decide whether their continued use is indicated. This may involve speaking to the patient or carer, checking their online records e.g., Summary Care Record (SCR), SystmOne, or speaking to their GP.
- Patients who have taken these medicines **for longer than four weeks** should not have this treatment stopped abruptly due to the risk of precipitating withdrawal symptoms, unless risks outweigh benefits e.g., the patient is severely intoxicated.
- Discontinuation should be planned and gradual over at least 4-6 weeks (longer in most cases).
- If there are concerns about the length of time a patient has been taking one of these medicines this should be referred to in any correspondence to the usual prescriber (e.g., GP, Community Mental Health Team).

New prescriptions

- Ensure non-pharmacological interventions are continued (see Appendix one – Practical Sleep Hygiene for Hospital Inpatients).
- Reserve for short prescribing duration to alleviate severe, disabling symptoms.
- If a prescription is required, it should be limited to a short time period (up to 7 days initially) and then reviewed.
- Start with the lowest licensed dose.
- A review/stop date should be stated clearly on the prescription.
- Ensure repeated PRN (as required) doses are recognized and reviewed in planned ward rounds and multidisciplinary team meetings.
- Out of hours doctors should not be expected to make decisions about continuation or prescription for discharge.
- Nursing and pharmacy staff should check with the prescriber if a benzodiazepine or z-hypnotic continues to be administered/requested after the stated review period.
- Intermittent use of z-hypnotics (every 2nd/3rd night) can help prevent tolerance developing. Explain to the patient the limitations of sleeping tablets. On initiation, consider a verbal 'contract' with the patient to manage expectations.
- Ideally, z-hypnotics should not be given/taken before midnight (to give the patient an opportunity to get to sleep without them).
- See Appendix 2 for a comparison of different benzodiazepines and z-hypnotics.

Discharge (TTO) and temporary leave prescriptions

- Review and aim to reduce or stop short-term benzodiazepine or z-hypnotics prior to discharge.
- Carefully consider if PRN benzodiazepines or z-hypnotics are still necessary for periods of leave or on discharge.
- The decision to prescribe benzodiazepines or z-hypnotics for periods of leave or discharge should only be made by a senior clinician in the treating team.
- If prescribed, the exact quantity to be supplied should be stated based on recent and likely usage.
- The minimum possible quantity should always be prescribed.
- If patients are discharged back to primary care on z-hypnotics or benzodiazepines, then the discharge summary should clearly state the likely duration of treatment and when this should be reviewed and stopped by the GP.
- Pharmacy will aim to confirm with the prescriber all discharge prescriptions for benzodiazepines and z-hypnotics where it is known that the patient was not taking these medicines prior to their hospital admission.

Outpatient prescriptions

- Exceptionally, there may be occasions where patients with severely disabling symptoms are prescribed longer courses under the supervision of a Consultant Psychiatrist.
- All out-patient repeat prescriptions (FP10s, community cards) should be reviewed regularly by the prescribing team to assess continuing need.
- Ensure no more than one prescriber is supplying z-hypnotics or benzodiazepines.
- All those involved in a patient's care (e.g., carers, care coordinator, community pharmacists) can play a valuable role in identifying chronic use of these medicines and bringing this to the attention of the prescribing team.

Management and Review of Long-Term Benzodiazepines and Z-hypnotics

Discussion with the patient

- Reiterate benefits of stopping (tolerance reduces effectiveness, and continuing treatment may only serve to prevent withdrawal symptoms, risk of withdrawal increases with higher doses and length of use, avoid adverse effects, reduce risk of accidents, and minimize risk of interactions with alcohol/illicit substances/other sedative medicines).
- Use [Should I stop my benzodiazepine or z-drug?](#) to support discussion.
- Explain the risks associated with the long-term use of benzodiazepines and z-hypnotics (cognitive impairment, anxiety, depression, reduced coping skills, emotional blunting and reduced social functioning)⁵.
- Explanation that withdrawal symptoms may occur following each reduction, but these symptoms tend to settle within a few days.
- It is not possible to estimate the severity of withdrawal; this will depend on several individual factors.
- Stress that benzodiazepines and z-hypnotics should not be stopped suddenly, and that the reduction will take time (months not weeks).
- Stress that abrupt withdrawal of benzodiazepines may produce confusion, toxic psychosis, convulsions, or a condition resembling delirium².
- Assess whether this is a suitable time for withdrawal (consider physical and mental health)
- Consider whether the withdrawal can be appropriately managed in primary care (is the patient committed and willing with adequate social support? Can they be reviewed regularly?)
- Seek specialist advice if there is a history of alcohol or other drug dependence, concurrent severe physical or mental health disorder or a history of drug withdrawal seizures.

If the patient is engaged and willing to taper

- Decide whether the patient can withdraw their current medicine without switching to diazepam first (see deprescribing algorithm below).
- Agree a reduction schedule with the patient; they should guide adjustments, so they remain comfortable and feel in control of the withdrawal.
- When considering frequency of reductions consider your capacity for follow up and review.
- Patients may experience withdrawal symptoms for several days after reduction so weekly reductions may be too quick.
- Withdrawal can take 4 weeks to 1 year (or longer)
- If symptoms relapse consider maintaining current dose for 1-2 weeks, then taper at a slower rate.
- The reduction becomes a larger proportion of the dose as the dose reduces. Patients may run into difficulty as they reach lower doses. Consider smaller dose reductions as the dose gets lower.
- If a person does not succeed on their first attempt, encourage them to try again.

What if the patient is not keen?

- Address any concerns the patient has.
- Show empathy; this can be a very sensitive topic.
- Explain that we now have better ways of working out how helpful medicines really are, and we know that a lot of things that we thought were helpful in the past have proved to be disappointing.
- Reassure that if a tapering trial does not work, we can think again.
- Allow time to reflect on information and arrange a further appointment if necessary.
- If, after reflection, the patient is still not keen then do not pressurize to stop and review again in 3 to 6 months.

Withdrawal symptoms

- The risk of withdrawal symptoms increases with longer use, higher dosage and higher potency medicines.
- May mimic the original condition being treated.
- **Benzodiazepines** – sweating, insomnia, loss of appetite, palpitations, perceptual disturbances, tremor, anxiety, depression, panic attacks, headache and nausea⁵
- A protracted withdrawal syndrome may occur in a minority of people (up to 15%); usually those who have taken benzodiazepines for many years.
- Established benzodiazepine dependence can be very difficult to treat. This may result in prolonged withdrawal symptoms and may even become a long-term state.
- **Z-hypnotics** – Rebound insomnia (with broken sleep and vivid dreams), impaired concentration, abdominal cramps, palpitations, perceptual disturbances, anxiety and depression⁵.

Managing withdrawal symptoms

- Provide reassurance – with slow tapering many people experience few or no withdrawal symptoms.
- If withdrawal symptoms are present, they will disappear in a few months for most people.
- Advise patient not to compensate by increasing intake of alcohol/illicit substances/other sedatives.

Anxiety

- Consider slower or suspending withdrawal until symptoms become manageable.
- Consider nonpharmacological management.
- Adjunct medications should not be routinely prescribed (but may be considered)

Depression

- Consider suspending withdrawal until the depression resolves.
- Treat as per NICE NG222⁶

Insomnia

- See information above on sleep hygiene and psychological therapies.

Benzodiazepine (BZD) or Z-hypnotic on repeat prescription (>4 weeks) Dependence Forming Medicines deprescribing algorithm.

Algorithm for use locally in Nottinghamshire with permission from PrescQIPP CIC.

Include: patients suitable for managed withdrawal with

- Insomnia on its own
- Anxiety

Consider if:

- Willing
- Committed
- Compliant
- Have adequate social support.
- Ensure that can be reviewed regularly.

Exclude (ensure regular review of therapy):

- Specialist/CMHT/substance misuse initiated.
- Potential substance misusers
- Patients who may be diverting some or all of their supply
- Suicide risk
- People with epilepsy
- Terminal illness
- Alcohol withdrawal
- Restless legs
- Dementia
- History of complicated drug withdrawal
- Short term use e.g., prior to flying, muscle relaxant, unmanaged anxiety, depression, physical or mental condition that may be causing or aggravating insomnia

Continue BZD or Z-drug.

Ensure directed communication: Review patient in clinic. Aim to ensure that the same HCP is seen.

- Use [NICE should I stop my benzodiazepine or z-drug?](#) decision aid to support review⁶.
- Reiterate benefits of stopping.
- Explain tolerance, adverse effects, and risks of continuing.
- Discuss potential risks, benefits, withdrawal plan, symptoms, and duration. (See [Royal College of Psychiatrists](#) or [MIND](#) for Z-drugs)
- Agree on treatment regimen (written plan)
- Arrange follow up appointments.
- Ensure practice staff are briefed on reducing regimen.

If unwilling to stop BZD or Z-drug: Do not pressurise to stop if not motivated. Address any concerns about stopping.

Review at a later date and reassess the persons motivation to stop.

Refer to sleep clinic or specialist with expertise in sleep medicine.

Insomnia¹

Use, [Sleep diaries](#), [sleeping health leaflets](#) and self-help strategies ([see NHS sleeping habits information](#)) to manage insomnia. See attachment 1 on self-care resources

Anxiety²

Low intensity psychological interventions:
Individual non-facilitated self-help – written or electronic
Individual guided self-help
Psychoeducational groups
High intensity psychological intervention (CBT or applied relaxation). See attachment 1 on self-care resources.

Taper and then stop BZD or Z-drug.

Withdrawal of BZD or Z-drug
Table 1

Short-acting BZD
Table 2

Monitor every 1-2 weeks for duration of tapering. Estimated time of withdrawal 8–12 weeks or longer. Be guided by the patient; if previously tried but failed, withdrawal can take 4 weeks to 1 year or longer.

If symptoms relapse consider maintaining current BZD or Z-drug dose for 1-2 weeks, then taper at a slower rate

Benzodiazepine (BZD) or Z-hypnotic on repeat prescription (>4 weeks) Dependence Forming Medicines (DFM) deprescribing algorithm

Algorithm for use locally in Nottinghamshire with permission from PrescQIPP CIC

Nottinghamshire Area Prescribing Committee

Table 1. Tapering BZD or Z-drug⁵

Taper slowly in collaboration with the patient, for example ~5-10% every two weeks, or 1/8th of dose fortnightly titrated according to the severity of withdrawal syndromes

Benzodiazepines	Reduction
Temazepam ≤ 20mg	Reduce daily dose by a quarter of a 10 mg tablet (2.5 mg) every 2 weeks. Consider temazepam 10mg/5ml liquid to achieve further reductions if needed.
Nitrazepam ≤ 10mg	Reduce daily dose by a quarter of a 5 mg tablet (1.25 mg) every 2 weeks. Consider nitrazepam 2.5mg/5ml liquid to achieve further reductions if needed.
Zopiclone ≤ 7.5mg	Reduce daily dose by a half of a 3.75 mg tablet (1.875 mg) every 2 weeks. Consider conversion to diazepam 2mg/5ml to achieve further reductions if needed

Table 2. For short acting BZD switch to diazepam⁵

For example, alprazolam, loprazolam, lormetazepam. This regimen may also be considered for people likely to experience difficulty in withdrawal due to dependency.

Transfer patient stepwise to an equivalent daily dose of diazepam preferably taken at night.	Diazepam 5 mg equivalent doses ^{3,5} ≡ alprazolam 250 micrograms ≡ clobazam 10 mg ≡ clonazepam 250 micrograms ≡ flurazepam 7.5–15 mg ≡ chlordiazepoxide 12.5 mg ≡ loprazolam 0.5–1 mg ≡ lorazepam 500 micrograms ≡ lormetazepam 0.5–1 mg ≡ nitrazepam 5 mg ≡ oxazepam 10 mg ≡ temazepam 10 mg ≡ zolpidem 10 mg ≡ zopiclone 7.5 mg
Reduce diazepam dose, usually by: 1–2 mg every 2–4 weeks (in patients taking high doses of benzodiazepines Initially it may be appropriate to reduce the dose by up to one-tenth every 1–2 weeks).	
If uncomfortable withdrawal symptoms occur, maintain this dose until symptoms lessen. Reduce diazepam dose further, if necessary, in smaller steps; steps of 500 micrograms may be appropriate towards the end of withdrawal. Then stop completely.	
For long-term patients, the period needed for complete withdrawal may vary from several months to a year or more	

Table 3: Evidence⁴

Benzodiazepine Dependence: Gradual withdrawal
Evidence: High

Use of several BZD: Switch to diazepam
Evidence: Good

Psychotherapy: Cognitive behavioural therapy and other approaches
Evidence: Good

Table 4. Resources

[PrescQIPP Benzo reduction programme \(2016\)](#)
[Canadian deprescribing benzodiazepine receptor agonist algorithms and guidelines](#)
[Ashton CH. Slow withdrawal schedules.](#)

References

1. NHS Clinical Knowledge Summary, Insomnia – Management. Last revised April 2015. Available at <https://cks.nice.org.uk/insomnia#!management> Accessed 09/11/19.
2. National Institute for Health and Care Excellence. CG113. Generalised anxiety disorder and panic disorder in adults: management. Jan 2011 updated June 2020. Available at www.nice.org.uk/CG113.
3. Joint Formulary Committee. British National Formulary (online) London: BMJ Group and Pharmaceutical Press; Available via <https://about.medicinescomplete.com/>.
4. Soyka M. Treatment of benzodiazepine dependence. *New England Journal of Medicine*. 2017; 376:1147–57.
5. NICE CKS. Benzodiazepine and z-drug withdrawal. Last revised May 24. Available at <https://cks.nice.org.uk/benzodiazepine-and-z-drug-withdrawal#!scenario>.
6. NICE (2023) Should I stop my benzodiazepine or Z-drug? Available at www.nice.org.uk.

Benzodiazepines and Hypnotics: Guidance on Prescribing and Deprescribing

V2.0 | Last reviewed: September 2024 | Review date: September 2027



Nottinghamshire Area Prescribing Committee

Driving

- Department of Health driving legislation is available at <https://www.gov.uk/drug-driving-law>
- There are DVLA regulations around benzodiazepine use and driving (note that doses outside of BNF guidance constitutes persistent misuse or dependence for licensing purposes whether in a programme of withdrawal or not).
- Advise patients not to drive if they feel drowsy, dizzy, or unable to concentrate.
- Counsel patients about the risks of impaired reaction times and injury even if they feel well.
- Remind that it is an offence to drive with more than a specified amount of benzodiazepine in your body, whether driving is impaired or not.
- Advise patients to keep evidence they are taking a benzodiazepine in accordance with medical advice (e.g., medication box with pharmacy label, evidence of repeat prescription).
- The DVLA provides no advice for people taking z-hypnotics.

References

1. NICE NG 215 (2022). Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. Available at www.nice.org.uk.
2. CSM Current Problems 1988, 21, 1-2. <https://benzo.org.uk/commit.htm>
3. Joint Formulary Committee. (2024). *British National Formulary*. Retrieved from <https://bnf.nice.org.uk/>.
4. British Association for Psychopharmacology. 2019. Consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update. *Journal of Psychopharmacology*, 33(8), pp923-947. Retrieved from https://www.bap.org.uk/pdfs/BAP_Guidelines-Sleep.pdf
5. NICE CKS. Benzodiazepine and z-drug withdrawal. Retrieved from <https://cks.nice.org.uk/topics/benzodiazepine-z-drug-withdrawal/>
6. NICE NG 222 (2022). Depression in adults: treatment and management. Available at www.nice.org.uk.
7. NICE (2023) Should I stop my benzodiazepine or Z-drug? Available at www.nice.org.uk

Benzodiazepines and Z-Hypnotics. Guidance on Prescribing and Deprescribing.

For the Management of Insomnia and Anxiety Disorders in Adults.

Intended for use by healthcare professionals. The flow charts and text boxes may not be accessible to some screen readers

Appendix One

Sleep hygiene in hospital

Sleep in hospital may be disrupted for a number of reasons^{1,2}:

- Disruption to normal sleep patterns (usual wake / sleep times).
- Proximity of other people.
- Noise (from other patients, staff, machines).
- Lighting – too dark during the day, too light at night.
- Worries (about diagnosis, care, treatment, concerns outside the hospital).
- Being in an unusual environment.
- Physical symptoms (such as pain, nausea, or breathlessness).
- Being woken for medical or nursing care during the night.
- Some medication may affect sleep patterns.

Rest and sleep are an important part of recovery and healing. Studies have suggested that sleep loss in hospital is associated with worse health outcomes, including cardio-metabolic derangements and increased risk of delirium in older patients¹.

In an acute care setting some common strategies to prevent insomnia may be more challenging to implement, however a thoughtful approach may allow integration of some of these into routine care.

At night:

- Avoid medical or nursing intervention unless necessary. Consider amending timing of medicine administration, blood tests, and observations if safe to do so.
- If possible, try to avoid diuretics and CNS stimulant medicines at bedtime (including steroids, nicotine, decongestants, and medicines for ADHD or narcolepsy).
- Encourage avoidance of caffeine (ensure decaffeinated options are available on the ward)
- Encourage toileting before bedtime.
- Actively address pain (one study suggested toileting and pain are the biggest causes of insomnia reported by patients in the hospital setting)¹
- Ensure a comfortable temperature – encourage patients to remove or request blankets.
- Ensure your patient is comfortable – assist with positioning, wearing own nightclothes if suitable.
- Avoid turning on lights, ensure conversations are at low volume and away from patient areas where possible. Minimise unnecessary phone calls (staff and patients).
- Patients may wish to bring ear plugs or eye masks into hospital (this is included in the NUH Packing for Hospital checklist for patients³).
- Encourage avoidance of screen time within 1 hour of bedtime.
- Encourage relaxation strategies. Offering a milky or non-caffeinated drink (avoiding large volumes of liquid at bedtime), soft music / spoken word (via headphones) and breathing techniques have all been shown to aid relaxation^{2,5}.

During the day:

- Encourage natural light (open blinds, curtains).
- Encourage gentle exercise if appropriate (e.g., sitting out, use of day room).
- Encourage avoidance of napping in the afternoon. If needed, naps are better taken earlier in the day and limited to 30 mins.

Hypnotics / sleeping tablets

New prescriptions of hypnotics for sleep alone should be avoided unless absolutely necessary and only used for the shortest possible time.

There can be a useful short-term window for hypnotics to encourage sleep / wake cycle if non-pharmacologic options are insufficient e.g. after surgery or in times of distress. Discuss this with your patient *before* prescribing and have a clear plan for stopping before discharge.

Benzodiazepines and Hypnotics: Guidance on Prescribing and Deprescribing		
V2.0	Last reviewed: September 2024	Review date: September 2027

Remember:

- Sleeping tablets do not just affect our sleep – they can also affect daytime alertness, memory, and coordination; they may increase harm from falls and reduce engagement in rehabilitation (e.g., therapy interventions.)
- Although many people assume that sleep medication will help them to function adequately the next day, there is little scientific evidence to support this.
- Effects on memory may also be at night – patients may report more sustained sleep due to not remembering waking episodes the following day⁴.

References

1. Stewart NH, Arora VM. 2018. Sleep in Hospitalized Older Adults. *Sleep Med Clin*, 13(1), pp127-135. doi:10.1016/j.jsmc.2017.09.012.
2. Tamrat R, Huynh-Le MP, Goyal M. 2014. Non-pharmacologic interventions to improve the sleep of hospitalized patients: a systematic review. *J Gen Intern Med*, 29(5), pp788-795. doi:10.1007/s11606-013-2640-9.
3. NUH Packing For Hospital Checklist, available at www.nuh.nhs.uk.
4. Adult self-help resource: *Managing Insomnia and Sleep Problems*. Nottinghamshire Healthcare NHS Trust, Loughborough University. Available at www.nuh.nhs.uk.
5. NHS patient information available at www.nhs.uk/conditions/insomnia (Accessed 31st July 2024).

Other local patient resources on sleep hygiene

- Nottingham Children's Hospital guidance: *A behavioural approach to managing sleep difficulties*. Community Paediatric Department. Available at www.nuh.nhs.uk

Benzodiazepines and Hypnotics: Guidance on Prescribing and Deprescribing

V2.0 | Last reviewed: September 2024 | Review date: September 2027

Appendix Two Comparison of Benzodiazepines and Z-hypnotics

Medicine	Usual adult dose for anxiety (per day) ¹	Usual adult dose for insomnia (per day) ¹	Approximate half-life (hours) ^{2 **}	Other information
Diazepam	2mg three times a day, increased if necessary to 15mg – 30mg daily in divided doses*	<i>Insomnia associated with anxiety:</i> 5mg – 15mg once daily at bedtime*	20-100 hours (36-200 hours for active metabolite)	In frail or older people consider very low starting dose
Lorazepam	1-4mg daily in divided doses*	<i>Insomnia associated with anxiety</i> 1-2mg once daily at bedtime*	10-20 hours	In frail or older people consider very low starting dose
Nitrazepam	N/A	5mg – 10mg daily before bedtime	15-38 hours	Avoid use in the elderly. Non-formulary in Nottinghamshire
Temazepam	N/A	10mg – 20mg daily before bedtime*	8-22 hours	Schedule 3 controlled drug
Zopiclone	N/A	7.5mg daily before bedtime*	5-6 hours	Slower onset than zolpidem but longer duration of action
Zolpidem	N/A	10mg daily before bedtime*	2 hours	Potent and quick acting (usually works within 15 minutes)

*For debilitated patients or older patients' lower doses (e.g., half adult doses) are recommended. See the BNF or Medication Summary of Product Characteristics (SPC) for further information.

**Half-life does vary between patients and can be longer in certain patient groups (e.g., renal impairment, older patients).

1. Joint Formulary Committee. (2020). *British National Formulary*. Retrieved from <https://bnf.nice.org.uk/>.
2. The Ashton Manual. (2007). Benzodiazepine equivalence table. Retrieved from <https://www.benzo.org.uk/bzequiv.htm>